India’s Dishman To Build $113 Million Plant For Anti-Cancer Drugs
This article was originally published in PharmAsia News
Dishman Pharmaceuticals said it would invest $113.1 million in facilities in a pair of Indian economic zones where it has land. The firm said in filings with the Bombay Stock Exchange it intends to begin work in each of the zones by the end of this year. Separately, Dishman said it is in the process of constructing the largest facility in Asia, dedicated to high-potency drugs such as those to treat cancer. The facility is to be built in conjunction with its existing Bavla plant in Gujarat. (Click here for more
You may also be interested in...
New chief medical officers take up positions at Abeona Therapeutics, Akcea Therapeutics and Oncologie, while there are new CFOs at Affimed, NGM Biopharmaceuticals, Phathom Pharmaceuticals, Oncologie and Syndax Pharmaceuticals.
Consumers in the UK can now self-select a version of Infirst's lipid-driven ibuprofen Flarin brand.
More news from across the sector, including Novartis's non-profit pledge on medicines and Zydus Cadila commencing Phase I vaccine trial.